For anyone tracking neurodegeneration research, the assumption has long been that brain damage causes symptoms where the damage sits. A finding in progressive supranuclear palsy challenges that model directly — suggesting that cognitive impairment can arise not from where toxic tau proteins accumulate, but from the functional disruption those deposits propagate to remote, connected cortical regions. This distinction has meaningful implications for how researchers might target therapies and measure disease progression.
Using a high-contrast tau-PET probe developed by the research team, investigators scanned 37 PSP patients and 48 healthy controls, then mapped tau deposition sites against a normative connectome — a reference atlas of typical brain functional connectivity. The analysis revealed that tau deposits, predominantly subcortical in PSP, are functionally wired to a shared cortical network even without being physically adjacent to it. This network aligned substantially with the canonical frontoparietal and action-mode networks, both critical for adaptive goal-directed behavior. Critically, the severity of cognitive deficits tracked with the strength of connectivity from tau sites to this remote cortical network — not with local atrophy — while motor symptom severity correlated with the extent of primary tau accumulation itself. The two symptom domains thus appear to have mechanistically separable substrates.
This work fits within an emerging paradigm sometimes called "network neurodegeneration," which posits that pathological proteins spread and exert influence along connectome architecture rather than simply at deposition sites. Prior work in Alzheimer's disease and Parkinson's have hinted at similar dynamics, but PSP's relatively discrete subcortical tau burden makes it an unusually clean model for isolating this mechanism. Key limitations include the modest cohort size and cross-sectional design, which prevents causal inference about propagation trajectories. Whether the identified cortical network disruption is reversible — and thus a viable therapeutic target — remains an open and important question. Nonetheless, this is a methodologically sophisticated, potentially paradigm-reorienting contribution to tauopathy research.